Form 4: Alnylam CEO Acquires Shares via RSU Vesting

Alnylam Pharmaceuticals CEO Yvonne Greenstreet acquired 5,921 shares of common stock following the vesting of restricted stock units on February 27, 2026.

Summary

• Yvonne Greenstreet, Chief Executive Officer and Director of Alnylam Pharmaceuticals, Inc. (ALNY), acquired 5,921 shares of common stock.
• The acquisition occurred on February 27, 2026, as a result of the vesting and release of restricted stock units (RSUs).
• These 5,921 shares represent the third and final tranche of a 17,763 RSU grant made on February 27, 2023, which vested ratably over three years.
• Following this transaction, Ms. Greenstreet directly beneficially owns 91,583 shares of Alnylam common stock.
• Additionally, Ms. Greenstreet indirectly beneficially owns 407 shares through a managed account under the issuer's 401(k) plan, resulting from matching contributions.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, reflecting a routine compensation mechanism that increases insider ownership and aligns executive interests with shareholders, without indicating any new fundamental changes to the company's operations or prospects.

Positives

• The transaction increases the direct beneficial ownership of common stock by the Chief Executive Officer, aligning management interests with shareholders.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

StockSavvy.ai notes that routine insider equity compensation transactions, such as the vesting of Restricted Stock Units (RSUs) and subsequent acquisition of common stock, are standard practice across the biotechnology and pharmaceutical sectors. These mechanisms are designed to align executive incentives with long-term shareholder value.

Related Party Transactions

• The vesting and acquisition of shares by Yvonne Greenstreet are part of her equity compensation package as an executive and director, representing a standard transaction between the company and a related party.

Stakeholder Impact

• Shareholders may view the increased direct ownership by the CEO as a positive sign of continued commitment and alignment of interests with the company's long-term success.

Next Steps

• Yvonne Greenstreet continues to hold beneficial ownership of Alnylam common stock, aligning her interests with the company's performance.

Key Dates

Recommendation

This Form 4 filing details a routine equity compensation event for the CEO, which does not provide new fundamental information to warrant a change in investment recommendation. The increase in direct beneficial ownership is a standard outcome of RSU vesting and does not alter the company's operational or financial outlook.

Keywords

Alnylam Pharmaceuticals, ALNY, Yvonne Greenstreet, Form 4, Restricted Stock Units, RSU vesting, insider transaction, equity compensation, common stock